Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
HWU, WEN-JEN
One or more keywords matched the following items that are connected to HWU, WEN-JEN
Item TypeName
Concept Interferon-alpha
Academic Article A phase II study of interferon-alpha 2b with dacarbazine, carmustine, cisplatin and tamoxifen in metastatic melanoma.
Academic Article Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma.
Academic Article Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon a-2b in patients with resected high-risk melanoma.
Academic Article A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
Academic Article Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
Academic Article Clinical results using biochemotherapy as a standard of care in advanced melanoma.
Academic Article Randomized trial of an allogeneic melanoma lysate vaccine with low-dose interferon Alfa-2b compared with high-dose interferon Alfa-2b for Resected stage III cutaneous melanoma.
Academic Article Does complete response to systemic therapy in patients with stage IV melanoma translate into long-term survival?
Academic Article Management of pegylated interferon alpha toxicity in adjuvant therapy of melanoma.
Academic Article Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
Academic Article Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-a in patients with metastatic melanoma.
Academic Article A phase I study of decitabine with pegylated interferon a-2b in advanced melanoma: impact on DNA methylation and lymphocyte populations.
Academic Article The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
Academic Article Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study.
Search Criteria
  • Interferon alpha